Chinese First-in-Class Dermatology Drug Launches Phase II Clinical Trial in Australia, Marking Breakthrough in Global Expansion

In May 2025, MDCE CRO’s overseas development service solution, Jeanne, successfully facilitated the completion of Site Initiation Visits (SIVs) for a Phase II clinical trial in Australia involving a breakthrough innovative candidate drug—a first-in-class dermatology product—from a leading Chinese innovative pharmaceutical company. This achievement has provided strong momentum for the compliant and efficient advancement of the project. The trial is planned to be conducted at three clinical research centers in Australia, with a target of enrolling at least 28 patients by the end of September. MDCE CRO has already secured ethical approvals and completed SIVs at the Australian sites, rapidly accelerating patient enrollment. Meanwhile, the company will continue to deepen its close collaboration with Australian research centers and Key Opinion Leaders (KOLs), laying a solid foundation for subsequent progression to global Phase III clinical trials or other related studies.

The launch of overseas multicenter clinical trials in Australia and the establishment of its first clinical research center mark a significant milestone for this innovative pharmaceutical company as it expands into the international market. MDCE CRO’s “Jeanne Solution” has strongly demonstrated its exceptional capability and efficient execution in providing affordable global expansion solutions. Over the past five years, the Jeanne Solution has successfully facilitated the overseas implementation of 23 Chinese innovative drug projects across countries and regions including the United States, Australia, Singapore, Hong Kong (China), the Middle East, and Southeast Asia, with cumulative patient management exceeding 500 individuals. In 2024, one project successfully completed Phase II trials and advanced to global Phase III development, vividly embodying the mission and vision of “making Chinese medical innovations benefit the world.”

As a core partner of this innovative pharmaceutical company, MDCE CRO leveraged its profound professional expertise to provide end-to-end specialized support for the Phase II clinical trial of its breakthrough innovative candidate drug in Australia. We not only ensured the efficient and high-quality advancement of the project but also consistently integrated a strategic focus on accelerating the drug’s market launch and maximizing its commercial potential.

During the establishment of the Australian research center for this project, the MDCE CRO team implemented meticulous management throughout the entire project lifecycle. In the initiation phase, the team strictly adhered to Australian regulatory standards and developed a comprehensive system of preliminary documents, including audit protocols and informed consent forms, to ensure compliant project advancement. Regarding drug management, the team exercised precise control to maintain stable supply chains and guarantee the continuity of the trial. Through this end-to-end oversight, MDCE CRO not only ensured the efficient and compliant operation of overseas clinical trials but also laid a solid documentary foundation for future marketing authorization applications, significantly reducing compliance and delay risks.

Leveraging extensive clinical resources in Australia, the MDCE CRO project team efficiently identified multiple leading target centers in the field of dermatology. The Site Initiation Visit (SIV) meeting organized by MDCE CRO was attended by the principal investigators, study coordinators from the research centers, sponsor executives, and the MDCE CRO project team. During the meeting, the project team provided comprehensive and in-depth training on the characteristics of the investigational product and trial procedures, while standardizing operational protocols. These initiatives not only laid a compliant data foundation for the clinical development of the product but also established a replicable model for subsequent site activations, thereby accelerating the overall project timeline.

MDCE CRO has placed commercial success at the strategic core since the project’s inception, empowering the global value realization of clients’ products through forward-looking layouts. The team collaborated with the client to define the market positioning and optimal market access pathways for this dermatology product in Australia and globally, efficiently initiating key overseas research centers to ensure the rapid acquisition of high-quality clinical data. This will significantly shorten the product’s time-to-market, helping the enterprise seize first-mover advantages in the global dermatology sector. By building academic barriers and planning clear commercialization pathways, MDCE CRO will continue to assist clients in maximizing their commercial returns.

From local innovation to global clinical validation, and from the accumulation of scientific data to the realization of commercial value, MDCE CRO serves as a professional bridge, facilitating the efficient global expansion of China’s medical innovations. In the future, we will continue to optimize our “Jeanne” solution for overseas commercialization of innovative drugs, closely monitoring global frontiers in R&D and market trends. We are committed to helping client enterprises not only maintain a leading position in the global market but also translate China-originated innovative therapies into tangible commercial outcomes and sustainable growth drivers. Ultimately, we aim to achieve a multi-dimensional win-win scenario characterized by elevated corporate value, improved global healthcare standards, and enhanced patient well-being.

MDCE CRO is a medical device R&D outsourcing service company with global clinical trials as its core business. Leveraging Harvard University’s global medical research resources and academic influence, MDCE CRO has built a comprehensive overseas service value chain to provide customized global market entry solutions for Chinese medical device enterprises. Its services encompass overseas clinical development strategy and design, management and operations of overseas clinical trials, overseas product registration, and international commercialization planning. Since its inception, MDCE CRO has successfully facilitated the overseas launch of more than 80 medical device and biopharmaceutical projects, generating cumulative overseas profits exceeding RMB 20 billion for its clients. Currently, MDCE CRO employs an in-house overseas clinical trial team of over 100 professionals, collaborates with more than 2,000 experts, and has partnerships with over 100 renowned overseas hospitals, covering regions including the European Union, North America, Australia and New Zealand, Southeast Asia, Japan and South Korea, the Middle East, and Africa.

For inquiries regarding overseas clinical and regulatory affairs, please scan the QR code to submit your information or contact us via the following methods:

● Phone: +86 18611648819

● Email: ask@mdcecro.com